First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 - Journal of Thoracic Oncology
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
ISPOR 2022: Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
US regulator scoops Asco with Bristol's lung cancer approval | Evaluate
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
First-line Nivolumab Plus Ipilimumab is Safe
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients☆ - ESMO Open
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Pharmaceuticals | Free Full-Text | First line Immunotherapy for Non-Small Cell Lung Cancer
Kaplan-Meier curves after matching adjustment for (A) overall survival... | Download Scientific Diagram
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
